Meeting
2023 ASCO Genitourinary Cancers Symposium
Survival outcomes of metastatic castration-resistant prostate cancer in Brazil (LACOG 1818).
Authors
Fernando Cotait Maluf
Hospital Beneficência Portuguesa, São Paulo, Brazil
Fernando Cotait Maluf , Suelen P. S. Martins , Deusdedit Cortêz Vieira Silva Neto , Gustavo Werutsky , Jose Augusto Rinck Jr , Diogo Assed Bastos , Roberto Odebrecht Rocha , Andre P. Fay , Roni de Carvalho Fernandes , Daniel da Motta Girardi , Daniel Vilarim Araujo , Augusto C. A. Mota , Aline Bobato Lara Gongora , Bruno Melo Fernandes , Ana Caroline Fonseca Alves , Cristina de Deus Anjos Tavares Sampaio , Andréa Lopes Ponte de Souza , Rafaela Gomes de Jesus , Gustavo Cartaxo de Lima Gössling , Andrey Soares
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Cancer Disparities
Clinical Trial Registration Number
NCT04962919
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS272)
DOI
10.1200/JCO.2023.41.6_suppl.TPS272
Abstract #
TPS272
Poster Bd #
P14
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A real-world registry of patients with metastatic castration-resistant prostate cancer (mCRPC): REMPRO study.
First Author: Francisco Gonzalez
Poster
2024 ASCO Genitourinary Cancers Symposium
Clinical outcomes with systemic therapy given after progression on prostate specific membrane antigen radioligand therapy (PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Soumaya Labidi
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) and tumors harboring androgen receptor (AR) ligand-binding domain (LBD) mutations.
First Author: Tyler F. Stewart
Poster
2024 ASCO Genitourinary Cancers Symposium
Predictors of PSA response to Lu177-PSMA-617 in metastatic castration-resistant prostate cancer.
First Author: Rebecca Hassoun